Doriane Henry was born in 1997 in Vesoul, France. She holds Master’s degrees in “Drug Sciences”. She is currently in her 3rd year of thesis in “Health and Biology” in the INSERM UMR1011 “Nuclear receptors, metabolic and cardiovascular diseases” under Pr Bart Staels and Dr Fanny Lalloyer’s guidance at the University of Lille, France. Her scientific activity is focused on the cross-talk between the liver and the heart, studying the influence of non-alcoholic fatty liver disease (NAFLD) progression on atherosclerosis development in preclinical murine models.

Professor Hilgendorf works as an interventional cardiologist and deputy of the medical director at Germany’s largest University Heart Center at Freiburg-Bad Krozingen. He leads the high-risk outpatient clinic and engages in clinical trials in the field of lipid therapy, heart failure, immunomodulation, and coronary and structural heart disease. Following his postdoctoral training at the MGH Center for Systems Biology, Boston, MA, USA, he established his own research group in Freiburg, Germany, studying the role of the innate and adaptive immune system in cardiovascular disease and the impact of traditional and non-traditional risk factors. Based on his seminal work, Ingo Hilgendorf was recently appointed Heisenberg Professor for Immunocardiology at the University of Freiburg, Germany.

Postdoctoral researcher in the functional cell profiling group at the Department of Anatomy, Faculty of Medicine, University of Helsinki. Has obtained her Ph.D. in Physiology and Neuroscience in 2019 from the University of Helsinki, Finland. Main research goal is to increase automation in cell biological research and apply this approach to elucidate how functioning of cellular mechanisms underlying hypercholesterolemia differs between individuals.

Prof. Kirsten B. Holven is head of section of clinical nutrition, department of nutrition, University of Oslo and head of research at the National Advisory Unit on Familial Hypercholesterolemia, Oslo University Hospital. Her main research interest is relating to women`s health especially focusing in women with FH, pregnancy and breastfeeding related issues, lipids through life cycle and dietary intervention studies. She has worked with research relating to patients with familial hypercholesterolemia (FH), for more than 25 years, with particular focus on impact on early cholesterol exposure in children with FH for later risk and women`s health issues. Identifying young women of childbearing age and their offspring with elevated LDL-C levels and initiating lipid-specific interventions may reduce the transgenerational cycle of dyslipidemia and CVD risk. Future prevention of cardiovascular risk in offspring may start before birth. By using comprehensive metabolic profiling, we can more precisely define phenotypes and understand the impact of different interventions. This information will enable us to give more precise medical treatment (personalized medicine) and dietary advices (personalized nutrition). She is a partner in the IAS Pediatric FH Register, in the EAS-FHSC (Familial Hypercholesterolemia Studies Collaboration) and the EAS Lipid Clinic Network.

Th. Hornemann is professor for clinical chemistry and head of research at the Institute for Clinical Chemistry, University Zurich. Prof. Hornemann and his team developed several unique methods to investigate the function and regulation of sphingolipid metabolism. He has long-standing experiences in analytical chemistry and LC-HRMS-based lipidomics and works on lipid signatures as diagnostic and prospective biomarkers in the field of cardio-metabolic diseases.

Dr. Jay D. Horton is a Professor of Internal Medicine and Molecular Genetics, and Director of the Center for Human Nutrition who holds the Distinguished Chair in Human Nutrition, the Scott Grundy Director’s Chair, and the Robert C. and Veronica Atkins Chair in Obesity and Diabetes Research at UT Southwestern. He obtained his B.S. and M.D. degrees from the University of Iowa and completed his internal medicine residency, gastroenterology fellowship, and Howard Hughes post-doctoral fellowship at UT Southwestern. Dr. Horton is a former PEW scholar and member of the American Society for Clinical Investigation and Association of American Physicians. He serves as a consulting editor for Arteriosclerosis, Thrombosis, and Vascular Biology and as an associate editor of The Journal of Lipid Research. In clinical digestive diseases, Dr. Horton has an interest in conditions that lead to fatty liver disease and obesity. Currently a major focus of the laboratory is to determine how transcriptional regulators of fat metabolism contribute to the development of fatty liver in various disease processes such as diabetes, obesity, and lipodystrophies. Dr. Horton’s research also delineated the function of PCSK9, a protein secreted into the blood that determines plasma cholesterol levels through its action on LDL receptors in liver.